NuCana PLC (NCNA) Stock Analysis

NuCana PLC (NCNA) is a publicly traded company in the HEALTHCARE sector. It trades at $2.07, carries a market capitalization of $9.03M, a price-to-earnings ratio of 0.02. This page summarizes the public market data, fundamentals, and frequently asked questions for NCNA, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $2.07
• Market Cap: $9.03M
• P/E Ratio: 0.02
• EPS: $134.15
• 52-Week High: $40.00
• 52-Week Low: $1.33

Market Sentiment

NuCana PLC currently has a Bullish sentiment score of 0.25.

About NuCana PLC

NuCana PLC is a clinical-stage biopharmaceutical firm headquartered in Edinburgh, UK, dedicated to developing transformative cancer therapies through its proprietary ProTide technology platform. This innovative approach is designed to improve the efficacy and safety of conventional chemotherapy agents, addressing significant unmet needs in oncology. The company’s lead candidates are currently undergoing clinical trials for various malignancies, including colorectal and pancreatic cancer. With...

GNG Research Analysis

GNG Research scores NuCana PLC (NCNA) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for NCNA.

Frequently Asked Questions

Does NCNA pay dividends?

NuCana PLC (NCNA) does not currently pay a regular dividend.

What is NCNA's P/E ratio?

NuCana PLC has a price-to-earnings (P/E) ratio of 0.02.

What is NCNA's market cap?

NuCana PLC (NCNA) has a market capitalization of $9.03M with a current stock price of $2.07.